Jaxteran

Dimethyl fumarate, the active ingredient in Jaxteran, is an immunomodulator presented as an oral tablet for oral use. It treats relapsing forms of multiple sclerosis and moderate to severe plaque psoriasis in adult patients. GNH USA supplies Jaxteran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jaxteran, an immunomodulator used in disease‑modifying therapy, is indicated for: - Relapsing‑remitting multiple sclerosis: reduces the frequency of clinical relapses and slows disability progression. - Plaque psoriasis (moderate to severe): improves skin lesions and decreases overall disease severity.

Common Side Effects: - Flushing: transient warmth and redness, often mitigated by taking with food. - Gastrointestinal discomfort: nausea, abdominal pain, or diarrhea. - Lymphopenia: mild reduction in lymphocyte count. - Headache: mild to moderate intensity. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Progressive multifocal leukoencephalopathy (PML): rare but potentially fatal brain infection. - Severe lymphopenia: markedly low lymphocyte counts increasing infection risk. - Hepatic injury: elevated liver enzymes or hepatitis. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin and mucosal reactions. - Acute pancreatitis: rare inflammation of the pancreas.

Before initiating therapy, clinicians should consider the following precautions: - Monitor lymphocyte counts: perform regular blood tests to detect lymphopenia. - Assess liver function: periodic hepatic enzyme monitoring is recommended. - Evaluate infection risk: avoid starting treatment in patients with active infections. - Counsel on flushing management: advise taking the tablet with food and avoiding alcohol. - Pregnancy and breastfeeding: use only if potential benefits outweigh risks. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Dimethyl fumarate may interact with several drug classes: Major Interactions (Avoid): - Live vaccines: contraindicated due to immunosuppressive effects. - Concurrent immunosuppressants (e.g., azathioprine): may increase infection risk. - Strong enzyme inducers (e.g., carbamazepine): may reduce dimethyl fumarate exposure. Moderate Interactions (Monitor Closely): - Antacids: may affect absorption; separate dosing by at least 2 hours. - NSAIDs: additive gastrointestinal irritation. - Non‑live vaccines: possible reduced efficacy; monitor immune response.